Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Ali Alqahtani, MD


June 17, 2022

The development of anti-BRAF targeted therapies represents another step toward a more personalized approach to the management of metastatic CRC. Patients with BRAF V600E-mutant metastatic CRC have a worse prognosis, with a median survival of only 12 months. Although anti-BRAF monotherapy has limited therapeutic efficacy, recent data suggest that combination therapy with a selective BRAF inhibitor (encorafenib) and the anti-EGFR monoclonal antibody cetuximab can improve objective response, progression-free survival, and overall survival in patients with BRAF V600E-mutant metastatic CRC after the failure of first-line treatment and beyond.

Learn more about emerging approaches in precision medicine for metastatic CRC.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.